[ET Net News Agency, 28 October 2021] Luye Pharma Group Ltd. (02186) said the group's
new central nervous system (CNS) drug LY03009 has obtained the approval from the Centre
for Drug Evaluation of the National Medical Products Administration in the People's
Republic of China to initiate clinical trials
LY03009 is indicated for the treatment of Parkinson's disease. It is developed on the
group's long-acting and extended release technology platform. (RC)